Standing Order
Novo Nordisk A/S

Dashboard

Novo Nordisk A/S

NVONYSE

For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.

Universal block

Live market data + trailing fundamentals.

Market cap$128B
Price$38.1752w $35.29 – $81.05
Conviction4/ 5
Revenue (TTM)$50.2B
Revenue growth YoY+5.6%
P/E (trailing)7.2
Gross margin80.6%
Operating margin43.1%
Net margin35.3%
52w price change-47.6%
Next earningsNov 4, 2026

Recent events

Material filings, federal awards, and regulatory activity. Impact is scored against market cap.

  • Sep 22
    Trial initiationClinicalTrials.gov

    Phase 3 trial (NCT07207811) of Coramitug initiated in ATTR amyloidosis heart failure; recruiting status.

  • Sep 21
    Trial readoutClinicalTrials.gov

    Phase 2 trial NCT06326047 of NN0519-0130 in Type 2 diabetes completed (status update 2026-09-21).

  • Sep 21
    Trial initiationClinicalTrials.gov

    Novo Nordisk Phase 1 trial NCT07829406 of NNC0642-1895 in healthy volunteers, not yet recruiting.

  • Sep 21
    Trial initiationClinicalTrials.gov

    Phase 3 trial NCT07830732 for Denecimig (Mim8) in acquired haemophilia A; status not yet recruiting.

  • Sep 21
    OtherSEC

    Novo Nordisk A/S filed Form 6-K with the SEC.

  • Sep 18
    Trial initiationClinicalTrials.gov

    Novo Nordisk trial NCT07632404 status updated to ENROLLING_BY_INVITATION for once-weekly insulin icodec switch study in type 2 diabetes.

  • Sep 18
    OtherClinicalTrials.gov

    Phase 3 trial NCT05135559 (concizumab, haemophilia A/B) status updated to ACTIVE_NOT_RECRUITING

  • Sep 18
    Trial initiationClinicalTrials.gov

    Novo Nordisk initiates Phase 1 trial NCT07220564 evaluating Inno8 doses in Haemophilia A patients; status recruiting.

  • Sep 18
    Trial initiationClinicalTrials.gov

    Post-marketing surveillance study of Rybelsus (oral semaglutide) in Korean T2DM patients, status NOT_YET_RECRUITING.

  • Sep 18
    Trial initiationClinicalTrials.gov

    Phase 3 trial NCT06609226 initiated for long-term Etavopivat in sickle cell disease or thalassemia (recruiting status).

  • Sep 17
    Trial initiationClinicalTrials.gov

    Novo Nordisk initiates Phase 3 trial NCT06612268 evaluating Etavopivat in sickle cell disease; status recruiting.

  • Sep 17
    OtherSEC

    Novo Nordisk A/S filed Form 6-K with the SEC on 2026-09-17.

  • Sep 16
    OtherClinicalTrials.gov

    Phase 3 trial NCT04082429 for concizumab in haemophilia without inhibitors status updated to ACTIVE_NOT_RECRUITING.

  • Sep 16
    Trial initiationClinicalTrials.gov

    Phase 3 trial NCT07822061 (AMAZE 10) for NNC0487-0111 recruiting in Japan for excess body weight.

  • Sep 16
    Trial initiationClinicalTrials.gov

    Novo Nordisk sponsors NCT06855563 Cities for Better Health Childhood Obesity Prevention Initiative, status ENROLLING_BY_INVITATION, phase NA.

  • Sep 16
    OtherClinicalTrials.gov

    Phase 2 trial NCT07639021 for NNC0662-0419 in obesity updated to ACTIVE_NOT_RECRUITING on 2026-09-16.

  • Sep 15
    Trial initiationClinicalTrials.gov

    Novo Nordisk initiates Phase 1 trial NCT07769489 assessing tolerability of 2-5 mL subcutaneous injections at varying rates.

  • Sep 15
    Trial initiationClinicalTrials.gov

    Novo Nordisk updates NCT07658417 to ENROLLING_BY_INVITATION: study of once-weekly insulin icodec vs daily basal in Type 2 diabetes.

  • Sep 15
    OtherSEC

    Foreign private issuer 6-K filed with SEC; no item details provided.

  • Sep 14
    Trial initiationClinicalTrials.gov

    Phase 3 trial NCT07817251 initiated (not yet recruiting) to study switching from semaglutide to Cagrisema in type 2 diabetes.

Not financial advice — research and opinion only. Disclosures